THE metabolic vulnerability index (MVX) may help identify patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at greatest risk of death and liver-related complications, according to a study of 1,613 patients spanning the full histological spectrum of the disease.
MASLD, a condition characterised by excess fat accumulation in the liver alongside metabolic dysfunction, affects an estimated 20-25% of adults. Although most patients do not develop severe liver disease, identifying those at highest risk remains a major challenge.
MVX Biomarker Sharpens MASLD Risk Prediction
Researchers evaluated MVX, a score reflecting inflammation and amino acid dysmetabolism, over a median follow-up of four years. Each 10-point increase in MVX was linked to a 2.7-fold higher risk of all-cause mortality and a 5.1 higher risk of liver-related mortality.
Higher MVX scores were also linked to an increased risk of hepatic decompensation, a rise in model for end-stage liver disease score to at least 15, and a decline in estimated glomerular filtration rate (eGFR) of 40% or more.
Importantly, combining fibrosis stage and MVX improved prediction of all-cause mortality, liver-related mortality, hepatic decompensation and hepatocellular carcinoma compared with fibrosis staging alone.
Beyond Fibrosis in MASLD Risk Assessment
Liver biopsy remains the reference standard for prognostic assessment in MASLD, but its limitations have driven interest in non-invasive tests. Existing tools such as the fibrosis-4 (FIB-4) index and liver stiffness measurement provide useful prognostic information but have recognised drawbacks, including reduced performance in some patient groups and limited availability of specialised imaging.
MVX demonstrated prognostic utility comparable to histological fibrosis staging for most assessed outcomes, except hepatic decompensation, and remained informative after accounting for fibrosis severity. The investigators also reported comparable performance between MVX and FIB-4 for predicting all-cause and liver-related mortality
The authors suggested that the findings challenge the long-standing view that fibrosis is the sole histological driver of outcomes in MASLD, highlighting a potential contribution from metabolic and inflammatory pathways.
Further Validation Needed Across Diverse Populations
The authors described the work as an initial step in biomarker qualification and emphasised that further validation is needed. Most participants were White, limiting generalisability to other populations, while performance at specific cut-offs and within subgroups such as patients with type 2 diabetes requires independent confirmation.
Nevertheless, the findings support further evaluation of the MVX biomarker as a non-invasive prognostic tool and may help inform future clinical trial design and risk stratification strategies in MASLD.
Reference
Siddiqui MS et al. The metabolic vulnerability index predicts outcomes in patients with metabolic dysfunction associated steatotic liver disease. Nat Commun. 2026;DOI:10.1038/s41467-026-73742-5.
Featured image: Lustre Art Group on Adobe Stock
- Author:
